บทบาทพยาบาลในการดูแลผู้ป่วยมะเร็งเมลาโนมาของชั้นคอรอยด์ ที่ได้รับการรักษาด้วยการฝังแร่รูทีเนียม-106

Panida Tukkin

Authors

Panida Tukkin Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Keywords:

choroidal melanoma, ruthenium-106 brachytherapy, ocular oncology nursing, radiation safety

Abstract

Introduction: Choroidal melanoma is the most common primary intraocular malignancy in adults. In Thailand, patients frequently present with advanced-stage tumors, complicating eye-sparing interventions and necessitating specialized nursing management.

Objectives: This article aims to analyze and synthesize current literature regarding the pathology, diagnosis, and treatment options for choroidal melanoma, and to develop comprehensive nursing guidelines for Ruthenium-106 (Ru -106) brachytherapy.

Key Issues: The main challenge is managing the care paradox, balancing strict radiation safety measures with the patient's need for psychological support. Nurses bridge this gap by integrating four phases of care: 1) proactive preparation; 2) radiation safety surveillance coupled with symptom management; 3) post-removal rehabilitation; and 4) empowerment for long-term self-care.

Conclusions: Clinical nurses play a vital role within the multidisciplinary team by providing holistic care, which is important for treatment success and maintaining the patient's quality of life.

Implications: Ophthalmic nurses should implement this comprehensive framework as a standard operating procedure to effectively deliver care and ensure safety for patients undergoing Ru - 106 brachytherapy.

Downloads

Download data is not yet available.

References

Wu M, Yavuzyigitoglu S, Brosens E, Ramdas WD, Kiliç E. Worldwide incidence of ocular melanoma and correlation with pigmentation-related risk factors. Investigative Ophthalmology & Visual Science 2023;64(13):45. doi: 10.1167/iovs.64.13.45.

Manchegowda P, Singh AD, Shields C, Kaliki S, Shah P, Gopal L, et al. Uveal melanoma in Asians: A review. Ocular Oncology and Pathology 2021;7(3):159-67.

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. New England Journal of Medicine 2021;385(13):1196-206.

Karimi S, Arabi A, Siavashpour Z, Shahraki T, Ansari I. Efficacy and complications of ruthenium-106 brachytherapy for uveal melanoma: A systematic review and meta-analysis. Journal of Contemporary Brachytherapy 2021;13(3):358-64.

Kulbay M, Marcotte E, Remtulla R, Lau THA, Paez-Escamilla M, Wu KY, et al. Uveal melanoma: comprehensive review of its pathophysiology, diagnosis, treatment, and future perspectives. Biomedicines 2024;12(8):1758. doi: 10.3390/biomedicines12081758.

Lim J, Teo AWJ, Siow TR, Chan KP, Tan GSW. Innovations in brachytherapy. Taiwan Journal of Ophthalmology 2025;15(1):62-72.

Memorial Sloan Kettering Cancer Center. About ocular brachytherapy [Internet]. 2024 [cited 2026 Apr 10]. Available from: https://www.mskcc.org/cancer-care/patient-education/about-ocular-brachytherapy

Davies C, Brown SL, Fisher P, Hope-Stone L, Heimann H, Dunn G, et al. Predictors of emotional distress in uveal melanoma survivors: A systematic review. Eye 2023;37(5):907-24.

Zaman FY, Ghaus A, Shackleton M, Kee D, Joshua AM, O'Day R, et al. Systemic surveillance guidelines for uveal melanoma: a systematic review. Clinical & Experimental Ophthalmology 2026;54(1):99-112.

Leister N, Löser J, Gostian AO, Gostian M, Rokohl AC, Fieber MA, et al. Postoperative pain following eye enucleation: A prospective observational study. Medicina 2024;60(4):614. doi: 10.3390/medicina60040614.

Martel A, Baillif S, Nahon-Estève S, Macagno N, Lassalle S, Hofman V, et al. Phantom eye syndrome: A multicenter study in 100 patients. Acta Ophthalmologica 2021;99(8):e1481-9. doi: 10.1111/aos.14657.

National Cancer Institute. Intraocular (uveal) melanoma treatment (PDQ®)–health professional version [Internet]. 2023 [cited 2026 Apr 10]. Available from: https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq

Jiang P, Purtskhvanidze K, Kandzia G, Neumann D, Lützen U, Siebert FA, et al. 106 Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma. Radiation Oncology 2020;15(1):183. doi: 10.1186/s13014-020-01621-4.

Semeniuk O, Yu E, Rivard MJ. Current and emerging radiotherapy options for uveal melanoma. Cancers 2024;16(5):1074. doi: 10.3390/cancers16051074.

De Brabandere M, Placidi E, Siebert FA, Carlsson Tedgren Å, Slocker Escarpa A, Tagliaferri L, et al. GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma - physicist survey. Radiotherapy and Oncology 2024;193:110114. doi: 10.1016/j.radonc.2024.110114.

Fallico M, Reibaldi M, Avitabile T, Longo A, Bonfiglio V, Chronopoulos A, et al. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefe's Archive for Clinical and Experimental Ophthalmology 2019;257(7):1547-54.

Somjai A, Youngcharoen P, Siripitayakunkit A. Factors associated with family caregiver’s fall preventive behaviors for older adults with low vision. Journal of Thailand Nursing and Midwifery Council [Internet]. 2025 [cited 2026 Apr 10];40(2):229-48. (in Thai). Available from: https://he02.tci-thaijo.org/index.php/TJONC/article/view/272466 (in Thai)

Rukwong P, Utsawapat M, Kachainchai S, Wisawatepnimit P. The development of a discharge planning model for end-stage cancer patients. Journal of Health and Nursing Research 2021;37(1):266-80. Available from: https://he01.tci-thaijo.org/index.php/bcnbangkok/article/view/249301 (in Thai)